RE: Flu still increasing6 Jan 2020 14:47
Whilst picking through the bones of that article, for anything interesting / implied, it led to me coming across the following research, whilst doing some Googling. The research/article was funded by the French National Research Agency as part of their Investments for the Future program: https://www.frontiersin.org/articles/10.3389/fimmu.2019.02760/full
The takeaway from it, and only reference to SNG, is this:
"In 2019, ONLY ONE phase 2 trial with an inhaled anti-infectious protein therapeutics is still ongoing (NCT03570359) assessing the efficacy of topical lung delivery of IFN-ß1a (SNG001, Synairgen/Astrazeneca), as an immunostimulant to treat COPD exacerbations."
We already know the initial indications from the trial are looking good, from earlier in the year, and the rest of the article just spells out why it's such a big market and desirable.